Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease.
Saved in:
| Title: | Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease. |
|---|---|
| Authors: | Smeijer, J. David1 (AUTHOR), Kohan, Donald E.2 (AUTHOR), Rossing, Peter3,4 (AUTHOR), Correa-Rotter, Ricardo5 (AUTHOR), Liew, Adrian6,7 (AUTHOR), Tang, Sydney C.W.8 (AUTHOR), de Zeeuw, Dick1 (AUTHOR), Gansevoort, Ron T.9 (AUTHOR), Ju, Wenjun10 (AUTHOR), Lambers Heerspink, Hiddo J.1,7 (AUTHOR) h.j.lambers.heerspink@umcg.nl |
| Source: | Cardiovascular Diabetology. 9/16/2023, Vol. 22 Issue 1, p1-9. 9p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
